Core Insights - The company, Jangxi Jindalai Environmental Protection Co., Ltd., reported a decline in revenue and profit for the fiscal year 2025 due to changes in market conditions and adjustments in risk management strategies, while maintaining a healthy overall financial status [1][2] - Despite short-term performance pressure, the company continues to focus on core business areas and technological innovation to counteract industry fluctuations [2] Financial Performance - In 2025, the company achieved total operating revenue of 338 million yuan, a decrease of 17.29% from 409 million yuan in the previous year [1] - The net profit attributable to shareholders was 96.08 million yuan, down 29.84% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 72.06 million yuan, reflecting a significant decline of 43.41% [1] - Basic earnings per share were 0.3479 yuan, a decrease of 29.83% compared to the previous year [1] - The weighted average return on net assets was 3.04%, down 1.30 percentage points from the previous year [1] Operational Strategy - The company emphasized project quality screening and risk management during the reporting period, prioritizing project quality and financial safety, which contributed to the decline in revenue and profit [2] - The significant drop in operating profit and net profit after deducting non-recurring gains and losses was closely related to the provision for credit impairment losses on long-aged accounts receivable, reflecting strict risk prevention measures [2] - The company remains committed to its core business of water environment governance, focusing on the treatment of domestic sewage and industrial wastewater, and adheres to a development strategy of "technology-driven, quality-first" [2] Technological Advancements - The company’s self-developed FMBR (Flexible Membrane Bioreactor) technology has been recognized as an advanced applicable technology by the Ministry of Industry and Information Technology, being the only project from Jiangxi Province to be included [2] - This technology offers significant advantages such as energy savings, land savings, cost reduction, and simplified management, and has been widely applied in over 30 provinces and more than 10 countries [2]

Core Viewpoint - Jindalai (688057.SH) reported a decline in financial performance for the fiscal year 2025, with total revenue of 338 million yuan and net profit attributable to shareholders of 96.08 million yuan, indicating a focus on project quality and risk management in a challenging market environment [1] Financial Performance - The company achieved total revenue of 338 million yuan, a decrease of 17.29% compared to the same period last year [1] - Net profit attributable to the parent company's shareholders was 96.08 million yuan, down 29.84% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 72.06 million yuan, reflecting a decline of 43.41% compared to the previous year [1] Strategic Focus - The company emphasized strengthening project quality screening and process risk control to ensure project quality and financial safety in response to the current market environment [1] Financial Health - Overall, the company's financial condition has remained healthy, with a good asset-liability structure, laying a solid foundation for sustainable development [1]

Core Viewpoint - Jindalai (688057.SH) reported a decline in key financial metrics for the fiscal year 2025, indicating challenges in the current market environment while maintaining a focus on project quality and risk management [1] Financial Performance - The company achieved total operating revenue of 338 million yuan, a decrease of 17.29% compared to the same period last year [1] - Net profit attributable to the parent company was 96.0075 million yuan, down 29.84% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 72.0583 million yuan, reflecting a decline of 43.41% from the previous year [1] Strategic Focus - The company is enhancing project quality screening and process risk control to ensure project quality and financial safety in response to the current market conditions [1] - Despite the recent declines, the company has maintained a healthy financial status and a solid asset-liability structure, laying a strong foundation for sustainable development [1]

Financial Performance - Total operating revenue for 2025 was CNY 338,291,229, a decrease of 17.29% compared to CNY 409,015,844.91 in the previous year[4] - Operating profit fell to CNY 97,419,481.49, down 33.57% from CNY 146,642,265.83 year-on-year[4] - Net profit attributable to shareholders was CNY 96,007,547.89, representing a decline of 29.84% from CNY 136,839,847.84 in the prior year[4] - Net profit excluding non-recurring gains and losses decreased by 43.41% to CNY 72,058,328.96 from CNY 127,332,354.10[4] - Basic earnings per share dropped to CNY 0.3479, down 29.83% from CNY 0.4958[4] - The return on equity decreased by 1.30 percentage points to 3.04% from 4.34%[4] Assets and Cash Flow - Total assets at the end of the reporting period were CNY 3,557,325,998.32, a decrease of 1.05% from CNY 3,595,198,341.28 at the beginning of the period[5] - The company is actively managing accounts receivable, resulting in a decrease in total accounts receivable and an increase in net cash flow from operating activities[6] Strategic Focus - The company has focused on water environment governance and has been recognized for its project in wastewater treatment, enhancing its position in the ecological protection sector[6] - The company aims to optimize its industrial structure and enhance risk resistance by exploring new growth areas while maintaining its core business[7]

Core Viewpoint - The company reported a total operating revenue of 338 million yuan for the fiscal year 2025, representing a year-on-year decline of 17.29%. The net profit was 96.07 million yuan, down 29.84% compared to the previous year [1]. Group 1: Financial Performance - Total operating revenue for 2025 was 338 million yuan, a decrease of 17.29% year-on-year [1]. - Net profit for the same period was 96.07 million yuan, reflecting a decline of 29.84% year-on-year [1]. Group 2: Strategic Focus - The company is concentrating on its core business of water environment management, adhering to a development strategy of "technology-driven, quality-first" [1]. - The company aims to leverage its core technological advantages to create benchmark projects [1]. Group 3: Project Recognition - The "Ruichang City West 30,000m³/d Sewage Treatment Plant" project, undertaken by the company, was recognized as a "2025 Typical Project for Ecological Environment Protection" by the China Environmental Protection Industry Association [1]. - The core technology used in the project was included in the first batch of "Advanced Applicable Technology List" by the Ministry of Industry and Information Technology of China [1].

Group 1 - The company, Jiangxi Jindalai Environmental Protection Co., Ltd., has approved an external investment plan to invest in Yunnan Jici Medical Technology Co., Ltd. [2][3] - The investment will be executed in three phases, with a total investment of RMB 150 million in the first phase, followed by RMB 50 million in the second phase, and the remaining funds after obtaining new drug clinical research approval [3][4] - The company aims to establish a concerted action relationship with Hu Min to jointly control Jici Medical in major decisions [3][4] Group 2 - The changes in the investment plan are expected to enhance the company's risk resistance and align with its long-term strategic development, without adversely affecting daily operations [5] - The investment is sourced from the company's own funds, which will not impose significant short-term cash flow pressure [8] - The company acknowledges the uncertainties and risks associated with drug development, including potential delays in clinical trials and regulatory approvals [9][10]

证券代码：688057 证券简称：金达莱 公告编号：2026-002 江西金达莱环保股份有限公司对外投资进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 投资标的名称 | 云南济慈医疗科技有限公司（以下简称"济慈医疗"） | | | --- | --- | --- | | 投资金额（万元） | 28,000 | | | 投资进展情况 | 完成 √交易要素变更 | 终止 | | 特别风险提示（如有） | 济慈医疗实际经营中可能受宏观经济、行业环境、市场变 | | | | 化等因素的影响，存在一定经营风险、财务风险、研发风险、 | | | | 政策风险等，未来业绩及收益仍存在不确定性。公司将密切关 | | | | 注投资事项的后续进展，积极防范和化解可能面临的各类风 | | | | 险，并按要求及时履行信息披露义务。敬请广大投资者谨慎决 | | | | 策，注意投资风险。 | | 一、对外投资基本情况 江西金达莱环保股份有限公司（以下简称"公司"）于2025年12月19日召开 第五届董事会第十一 ...

Core Viewpoint - The company plans to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., with changes in investment elements [1] Investment Details - The investment will be made in three phases: 150 million yuan upon completion of business registration, 50 million yuan after obtaining IIT permission, and the remaining amount after IND approval [1] - The board of directors has approved the aforementioned matters [1] Agreement and Risks - The company intends to reach a concerted action agreement with Hu Min [1] - Jici Medical faces operational, financial, research and development, and policy risks, leading to uncertainties in future performance and returns [1]

Group 1 - The stock price of Jindalai (688057) closed at 12.65 yuan on January 9, 2026, reflecting a 3.52% increase from the previous week's price of 12.22 yuan [1] - The highest intraday price for Jindalai on January 9 was 12.71 yuan, while the lowest intraday price on January 5 was 12.23 yuan [1] - Jindalai's current total market capitalization is 3.491 billion yuan, ranking 70th out of 106 in the environmental governance sector and 4329th out of 5182 in the A-share market [1] Group 2 - The company plans to invest 280 million yuan in Jici Medical, acquiring a 34.00% stake, focusing on autologous cell technology research and development [2] - Jindalai is also increasing its investment in Zhongke Hongtai to enter the vascular interventional surgical robot field, with products currently undergoing special review procedures for national innovative medical devices [2]

Core Viewpoint - The recent investment by Jindalai (688057.SH) in stem cell company Jici Medical has raised questions from the stock exchange regarding the reasonableness of Jici Medical's immediate revenue generation and the significant increase in transaction valuation [1] Group 1: Revenue Generation - Jici Medical, established in August 2025, reported revenues of 8.6911 million yuan and 11.2273 million yuan for 2024 and the first three quarters of 2025, respectively, primarily from patent licensing and technical services [1] - The revenue sustainability and customer concentration risk have been highlighted, with the largest customer, an affiliate named Zhendijici, contributing 89.75% of revenue in 2024 and 99.02% in the first three quarters of 2025 [1] - The company plans to reduce dependency on this major client by expanding its partnerships with other institutions in the future [1] Group 2: Valuation Concerns - The transaction valuation for Jici Medical is set at 543.5961 million yuan, significantly higher than its book net assets, primarily due to the valuation of 30 unaccounted patents using the income approach [1] - The assessment assumes that revenue from the rFib cell storage business will grow from 250 million yuan in 2026 to 5 billion yuan by 2036, with a royalty rate for the patented technology set at 17.13% [1] - The company emphasized that this valuation is lower than comparable industry cases, such as Betta Pharmaceuticals' acquisition of RepuMed, which had a static price-to-sales ratio of 989 times, while this transaction is at 62.54 times [1]